What Has Tesamorelin Proved in People?

What is the clearest answer on tesamorelin for your health?

Trials found that tesamorelin lowered deep belly fat in certain adults with HIV ^[13][15][17]. Their fat had shifted after treatment for HIV.

The FDA approved tesamorelin for that one use. The same trials do not prove general weight loss, longer life, or sharper thinking.

Tesamorelin copies a hormone your brain makes. That hormone asks the pituitary, or growth gland, to send out growth hormone.

The medicine does not add growth hormone from outside your body. Instead, your gland sends out more in its usual pulses.

That difference may matter, but a body process is not proof by itself. You still need a trial in the kind of person making the claim.

What is tesamorelin made to copy?

Tesamorelin is a 44-amino-acid peptide, built from tiny parts joined into proteins. It copies a hormone that starts the body’s growth process.

One added part protects tesamorelin from breaking down too fast in blood. The approved medicine is given as a daily shot under the skin.

Tesamorelin reaches the growth gland near the base of your brain. The gland then sends out more of your own growth hormone.

Tesamorelin lets growth hormone rise and fall in short bursts. A direct dose tends to keep the hormone raised more steadily.

Neither pattern is better by itself. A study must find whether either pattern brings a better result for people like you.

How does tesamorelin affect growth hormone and fat?

Tesamorelin acts on certain cells in the growth gland. Those cells then send out more growth hormone in the body’s usual short bursts.

Growth hormone tells the liver to make insulin-like growth factor 1, also called IGF-1. That protein helps the body grow and break down fat.

The clearest change was in deep belly fat, not body weight as a whole. That is why the approved use stays narrow.

One small trial followed 13 healthy men for two weeks. Growth hormone and IGF-1 both rose after tesamorelin ^[16].

The rise in IGF-1 did not clearly change fasting blood sugar or how the body used insulin. The short study can’t promise the same result over longer use or in other people.

What happened to people in the main tesamorelin trials?

Five-trial review, 2026. The review joined five trials in people with the HIV-related fat disorder. Deep belly fat fell, and a 95% math range showed the exact amount was not certain ^[13].

Trunk fat and liver fat fell, while lean tissue rose. No serious harm stood out in the review.

Approval and liver review. The United States approved tesamorelin in 2010 for excess belly fat in adults with HIV. A government review found no clear case of liver harm caused by the drug ^[14].

Main trial, 2014. This 6-month trial included 50 adults with HIV. Tesamorelin went to 28 people, while 22 received placebo.

The 2 milligrams each day cut 42 centimeters squared more deep belly fat than placebo ^[15]. That figure is an area on a body scan, not a waist measurement.

Liver fat also fell. Still, one trial cannot settle the question for all adults.

Healthy men, 2011. Researchers studied 13 men in a 2-week trial. Growth hormone rose after tesamorelin ^[16].

The liver-made protein IGF-1 rose by 181 micrograms per liter. Blood sugar and the body’s use of insulin did not clearly change.

This 13-person study was small and short. It cannot settle long-term safety or effects in other groups.

Longer study, 2008. Researchers followed 273 people taking 2 milligrams each day and 137 taking placebo. During a 52-week program, deep belly fat stayed 18% below the starting amount ^[17].

Fat returned after treatment stopped. Blood-sugar changes were not large enough to matter in care.

What do people report, and what risks are known?

Reports from people using tesamorelin outside care haven’t been checked in a controlled study. There is no sound group of user reports to sum up.

That leaves no fair list of usual benefits or harms from such reports. The cautions below come from trials and government records instead.

• FDA approval is narrow. It covers deep belly fat from an HIV-related fat disorder ^[14]. The approval doesn’t prove broad weight loss.
• The main trials studied adults with HIV. Results in people without HIV may differ ^[13][15][17]. Your own health may change both benefit and risk.
• The fat returns after stopping. Tesamorelin did not make a one-time change ^[17]. The longer trial saw fat build up again.
• A liver-made growth protein rises. The protein is IGF-1, and it helps cells grow. Since IGF-1 supports growth, active cancer bars use, though trials up to 52 weeks found no clear added cancer risk ^[16].
• Blood-sugar findings differ. Neither the 52-week work nor the short test in healthy men showed a change large enough to guide care ^[17][16]. A doctor may still watch your blood sugar.
• Thinking and memory claims are not settled. Small aging studies cannot borrow proof from the HIV trials. Those studies asked a different health question.
• Sports rules bar tesamorelin. Tested athletes can face a ban in or out of a contest. That rule stands even when a use is prescribed.

How does tesamorelin compare with the other two?

Tesamorelin sits between the other two for human proof. It has repeated human trials ^[13][15][17] and one FDA-approved use.

MOTS-c has no finished trial of shots in people. Semaglutide has large trials across several common health problems.

Tesamorelin works through the growth gland. It does not copy the gut hormone GLP-1 used by semaglutide or work like MOTS-c in cells.

The key limit is who took part. Trials support adults whose HIV care changed their body fat, not every person seeking weight loss.

The comparison page puts all three records in one place. You can judge each claim by the people actually studied and the length of each trial.